Four new high-lysine barley mutants, the variety 'Lysimax', with the high-lysine gene lys3a and the mutants mother variety 'Sultan' were grown in a field trial in 1993 at Risø, Denmark. Mutants 609, 1242, 1385 and 1405 yielded in the range of 89 to 98 percent and cv 'Lysimax' yielded 102 percent of cv 'Sultan' (100 percent). One-thousand kernel weights for the mutants were in the range of 87 to 97 percent and cv 'Lysimax' 83 percent of cv 'Sultan' (100 percent). Protein contents of the mutants were slightly higher, in the range of 13.2 to 13.6 percent, than of cv 'Sultan' (13.1 percent) and 'Lysimax' which had a protein content of 12.6 percent. Fat content was higher in 'Lysimax' and in the mutants except for mutant 1385 than in cv 'Sultan' while dietary fibre contents of the barleys were similar. The levels of beta-glucans and starch were usually lower in 'Lysimax' and in the mutants. The highest lysine levels: 4.6, 4.0 and 3.7 g/16 g N occurred in cv 'Lysimax' and mutants 609 and 1405 compared to 3.3, 3.3 and 3.2 for cv 'Sultan' and mutants 1242 and 1385, respectively. Mutants 609 and 1405 and cv 'Lysimax' also had higher levels of threonine, histidine and valine. The increased lysine contents resulted in large, at most 20 percent, increases in biological value; 88.8, 81.7 and 78.3 percent for cv 'Lysimax' and mutants 609 and 1405 compared to 74.2 percent for cv 'Sultan'. True protein digestibilities and energy digestibilities were slightly lower in 'Lysimax' than in 'Sultan', 5.3 and 4.3 percentage units, respectively. It is concluded that the development of high-lysine barley varieties is very beneficial for meeting the requirements of indispensable amino acids for humans and monogastric animals. In addition, nitrogen excretion into the environment is drastically reduced due to the higher biological values of the mutants.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/BF01088313 | DOI Listing |
Pediatr Res
January 2025
Department of Neurology, Children's Hospital Affiliated to Capital Institute of Pediatrics, Beijing, China.
Background: CblC type methylmalonic aciduria (cblC disease) is the most common inborn error of vitamin B12 metabolism and due to mutations in the MMACHC gene. The earlier the diagnosis, the better the prognosis. Therefore, convenient and inexpensive detection method is needed.
View Article and Find Full Text PDFJ Neuroinflammation
December 2024
Departament de Biomedicina, Facultat de Medicina, Institut de Neurociències, Universitat de Barcelona, 08036, Barcelona, Spain.
Schizophrenia is a complex multifactorial disorder and increasing evidence suggests the involvement of immune dysregulations in its pathogenesis. We observed that IKZF1 and IKZF2, classic immune-related transcription factors (TFs), were both downregulated in patients' peripheral blood mononuclear cells (PBMCs) but not in their brain. We generated a new mutant mouse model with a reduction in Ikzf1 and Ikzf2 to study the impact of those changes.
View Article and Find Full Text PDFLancet Microbe
October 2024
National Institute for Medical Research, Dar es Salaam, Tanzania; Department of Immunology and Infectious Diseases, Harvard T H Chan School of Public Health, Boston, MA, USA; Department of Biochemistry, Kampala International University in Tanzania, Dar es Salaam, Tanzania. Electronic address:
Oncologist
July 2024
Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, United States.
Background: The role of tyrosine kinase inhibitors (TKIs) in early-stage and metastatic oncogene-driven non-small cell lung cancer (NSCLC) is established, but it remains unknown how best to integrate TKIs with concurrent chemoradiotherapy (cCRT) in locally advanced disease. The phase 2 ASCENT trial assessed the efficacy and safety of afatinib and cCRT with or without surgery in locally advanced epidermal growth factor receptor (EGFR)-mutant NSCLC.
Patients And Methods: Adults ≥18 years with histologically confirmed stage III (AJCC 7th edition) NSCLC with activating EGFR mutations were enrolled at Mass General and Dana-Farber/Brigham Cancer Centers, Boston, Massachusetts.
Commun Biol
May 2024
Department of Molecular Oncology, Institute for Advanced Medical Sciences, Nippon Medical School, Tokyo, Japan.
STAT3 is constitutively activated in many cancer types, including lung cancer, and can induce cancer cell proliferation and cancer stem cell (CSC) maintenance. STAT3 is activated by tyrosine kinases, such as JAK and SRC, but the mechanism by which STAT3 maintains its activated state in cancer cells remains unclear. Here, we show that PRMT5 directly methylates STAT3 and enhances its activated tyrosine phosphorylation in non-small cell lung cancer (NSCLC) cells.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!